Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04932291 · ClinicalTrials.gov registry record · Phase 2
Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population
A Phase 2 study, sponsored by Oryzon Genomics S.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 211
- Enrollment target
NCT04932291: Completed Phase 2 study, sponsored by Oryzon Genomics S.A..
NCT04932291 is a Phase 2 study that has completed, run by Oryzon Genomics S.A.. The registered enrollment target is 211 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04932291, a Phase 2 study, has completed, sponsored by Oryzon Genomics S.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 211 participants
- Enrollment target
Study Summary
PORTICO is a Phase IIb study to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population.
Primary Outcome
Change on the CGI-S A/A from Baseline to average of Weeks 8 to 12, between the active treatment arm (Vafidemstat 1.2 mg) and the placebo arm (full analysis set). * Full scale name: Clinical Global Impression-Severity focused on Agitation/Aggression * Scale construct: the CGI-S A/A is a clinician's global rating of the BPD patients' severity of agitation and aggression symptoms at the time of evaluation. * Scale items: 1. * Scale range values: 0 to 7. Higher scores reflect greater severity of BP
Interventions
- DRUG Placebo
- DRUG vafidemstat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2021-03-26 |
| Est. Completion | 2023-11-13 |
| Phase | Phase 2 |
What the finished NCT04932291 record still lists
NCT04932291 is an interventional study that assigns participants to a tested intervention. The registered 211 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04932291 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04932291 about?
NCT04932291 is a clinical study titled "Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population". PORTICO is a Phase IIb study to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population.
What is the current status of trial NCT04932291?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 211 participants. The study started on 2021-03-26. Estimated completion is 2023-11-13.
What interventions are being tested in trial NCT04932291?
The interventions under investigation include: Placebo (DRUG), vafidemstat (DRUG).
Who is sponsoring clinical trial NCT04932291?
This trial is sponsored by Oryzon Genomics S.A., which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04932291's enrollment target sits among peer trials
211 290th of 2000 higher than 1,711 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06698796 · 211 participants · Phase 3
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI